Kohjin Bio Co., Ltd. Logo

Kohjin Bio Co., Ltd.

A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.

177A | T

Overview

Corporate Details

ISIN(s):
JP3283630006
LEI:
Country:
Japan
Address:
坂戸市千代田5−1−3
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kohjin Bio Co., Ltd. is a biotechnology company specializing in the development, manufacture, and sale of products for life sciences research and clinical applications. Its core offerings include tissue and cell culture media, media for microbial testing, and in-vitro diagnostic reagents. The company also provides animal-derived biological materials such as blood and serum. A key area of focus is regenerative medicine and cell therapy, where Kohjin Bio operates as a leading Contract Development and Manufacturing Organization (CDMO) in Japan, producing specialized culture media. Additionally, the company offers bioservices, including immunology contracts and the processing of cells for cancer immune therapies through partnerships with medical institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:30
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-13 07:30
Interim Report
半期報告書-第45期(2025/04/01-2026/03/31)
Japanese 215.4 KB
2025-06-27 08:30
Post-Annual General Meeting Information
臨時報告書
Japanese 23.8 KB
2025-06-24 09:09
Governance Information
内部統制報告書-第44期(2024/04/01-2025/03/31)
Japanese 25.0 KB
2025-06-24 09:08
Registration Form
確認書
Japanese 9.0 KB
2025-06-24 09:06
Annual Report
有価証券報告書-第44期(2024/04/01-2025/03/31)
Japanese 1.8 MB
2024-11-14 07:30
Regulatory News Service
確認書
Japanese 8.9 KB
2024-11-14 07:30
Interim Report
半期報告書-第44期(2024/04/01-2025/03/31)
Japanese 200.4 KB
2024-07-04 02:15
Post-Annual General Meeting Information
臨時報告書
Japanese 27.7 KB
2024-06-28 08:09
Registration Form
確認書
Japanese 9.0 KB
2024-06-28 08:00
Annual Report
有価証券報告書-第43期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-04-25 05:44
Major Shareholding Notification
臨時報告書
Japanese 21.2 KB
2024-04-16 08:01
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-04-08 03:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 1.8 MB
2024-03-22 07:00
Registration Form
有価証券届出書(新規公開時)
Japanese 3.5 MB

Automate Your Workflow. Get a real-time feed of all Kohjin Bio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kohjin Bio Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kohjin Bio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France
ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden
ABLI
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapies for oncology & ophthalmology.
United States of America
ABP
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France
AB
ACADIA PHARMACEUTICALS INC Logo
Develops and commercializes innovative therapies for CNS disorders and rare diseases.
United States of America
ACAD
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
Developing cytisinicline, a plant-based treatment for smoking cessation and nicotine addiction.
United States of America
ACHV
AC Immune SA Logo
Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
A clinical-stage biopharma developing novel drugs for immuno-inflammatory diseases.
United States of America
ACRS
Actinium Pharmaceuticals, Inc. Logo
Develops targeted radiotherapies for advanced cancers like AML and prostate cancer.
United States of America
ATNM

Talk to a Data Expert

Have a question? We'll get back to you promptly.